RGNX
RGNX
US75901B1070
REGENXBIO Inc.
Loading chart...
Elevated Business & Solvency Risk

Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 45/100).

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Largely moves in line with the broader market.

Beta (Market Relation)
1.13x
Above average
Volatility (5Y p.a.)
73.5% p.a.
5-Year Horizon
Max Drawdown (5Y)
-86.4%
5-Year Horizon
Sharpe Ratio
-0.36
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -33.8%
3 Years 82.5% -78.4% -0.28 -20.4%
5 Years 73.5% -86.4% -0.36 -23.9%
10 Years 70.0% -93.5% -0.14 -7.6%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 349%.
Elevated Short-Term Volatility: 3Y volatility (82.5%) is noticeably higher than the 5Y average (73.5%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (73.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -93.5% in the extended horizon.
ende